Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.  Nuvo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration.



Contact Information
Investor Relations
Email: [email protected]

Latest

Nov 16, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results

- Q3 2020 Adjusted Total Revenue - $16.7 million - - Q3 2020 Adjusted EBITDA - $6.6 million - - Blexten Canadian Prescriptions Increased 30% Year-Over-Year - - Cambia Canadian Prescriptions Increased ...


Nov 02, 2020, 07:30 ET Nuvo Pharmaceuticals™ Announces Third Quarter 2020 Results Release Date and Conference Call Details

MISSISSAUGA, ON, Nov. 2, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of ...


Oct 05, 2020, 07:30 ET Nuvo Pharmaceuticals® to Webcast Live at VirtualInvestorConferences.com October 8th

- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com - MISSISSAUGA, ON, Oct. 5, ...


Sep 14, 2020, 07:30 ET Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th

- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com - MISSISSAUGA, ON, Sept....


Sep 09, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces The Canadian Commercial Launch of Suvexx™ - For The Acute Treatment of Migraine

- Combination of sumatriptan succinate and naproxen sodium in a single tablet - MISSISSAUGA, ON, Sept. 9, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI); (OTCQX: NRIFF), a...


Aug 10, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces Second Quarter 2020 Results

٠ Q2 2020 Adjusted Total Revenue - $18.0 million ٠ ٠ Q2 2020 Adjusted EBITDA - $7.6 million ٠ ٠ Blexten Canadian Prescriptions Increased 34% Year-Over-Year ٠ ٠ Cambia Canadian Prescriptions Increased ...


Jul 27, 2020, 07:30 ET Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details

MISSISSAUGA, ON, July 27, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio...


May 12, 2020, 16:20 ET Nuvo Pharmaceuticals® Announces Director Election Results of its Annual & Special Meeting of Shareholders

MISSISSAUGA, ON, May 12, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a Canadian-focused healthcare company with global reach and a diversified portfolio of...


May 11, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces First Quarter 2020 Results

٠ Q1 2020 Adjusted Total Revenue - $18.9 million ٠ ٠ Q1 2020 Adjusted EBITDA - $8.0 million ٠ ٠ Blexten Canadian Prescriptions Increased 54% Year-Over-Year ٠ ٠ Cambia Canadian Prescriptions Increased ...


Apr 27, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces First Quarter 2020 Results Release Date and Virtual Annual & Special Meeting of Shareholders

MISSISSAUGA, ON, April 27, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of ...


Mar 31, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces Approval of Takeda's Cabpirin Tablets in Japan, Triggering a US$2.0 Million Milestone Payment due in Q2 2020

- Takeda holds a non-exclusive license to Nuvo's Yosprala™ patent permitting it to market Capbirin in Japan - MISSISSAUGA, ON, March 31, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company)...


Mar 23, 2020, 10:00 ET Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum March 26th

- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com - MISSISSAUGA, ON, March...


Mar 04, 2020, 17:05 ET Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States

MISSISSAUGA, ON, March 4, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of...


Feb 27, 2020, 17:05 ET Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx™ For The Acute Treatment of Migraine

- Canadian Launch Anticipated in the Second Half of 2020 - MISSISSAUGA, ON, Feb. 27, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a Canadian focused...


Feb 25, 2020, 07:30 ET Nuvo Pharmaceuticals® Announces 2019 and Fourth Quarter Results

٠ Fiscal Year 2019 Adjusted Total Revenue - $74.7 million ٠ ٠ Fiscal Year 2019 Adjusted EBITDA - $27.2 million ٠ ٠ Blexten Canadian Prescriptions Increased 61% Year-Over-Year ٠ ٠ Cambia Canadian...


Feb 11, 2020, 14:27 ET Nuvo Pharmaceuticals™ Responds to Market Activity

MISSISSAUGA, ON, Feb. 11, 2020 /CNW/ - At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a...


Feb 11, 2020, 07:30 ET Nuvo Pharmaceuticals™ Announces Fourth Quarter 2019 Results Release Date and Conference Call Details

MISSISSAUGA, ON, Feb. 11, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of...


Jan 07, 2020, 07:30 ET Nuvo Pharmaceuticals™ Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of...


Nov 11, 2019, 07:30 ET Nuvo Pharmaceuticals™ Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents

VIMOVO Litigation to Continue MISSISSAUGA, ON, Nov. 11, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach...


Oct 31, 2019, 07:00 ET Nuvo Pharmaceuticals™ Announces 2019 Third Quarter Results

· Third Quarter Adjusted Total Revenue - $18.9 million and $55.1 million year-to-date · · Third Quarter Adjusted EBITDA - $7.8 million and $18.7 million year-to-date · · Third Quarter Gross Profit -...


Oct 17, 2019, 08:00 ET Nuvo Pharmaceuticals™ Announces Third Quarter 2019 Results Release Date and Conference Call Details

MISSISSAUGA, ON, Oct. 17, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of...


Sep 09, 2019, 08:00 ET Nuvo Pharmaceuticals™ Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference

- Tuesday, September 10, 2019 – 4:15 p.m. ET - MISSISSAUGA, ON, Sept. 9, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company...


Sep 04, 2019, 08:00 ET Nuvo Pharmaceuticals™ to Present at H.C. Wainwright Global Investment Conference

MISSISSAUGA, ON, Sept. 4, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of...


Aug 14, 2019, 07:30 ET Nuvo Pharmaceuticals™ Announces 2019 Second Quarter Results

• Second Quarter Adjusted Total Revenue - $19.1 million • • Second Quarter Adjusted EBITDA - $5.7 million • • Second Quarter Gross Profit - $9.6 million • - Nuvo to Host Conference Call/Audio Webcast ...


Jul 31, 2019, 07:30 ET Nuvo Pharmaceuticals™ Announces Second Quarter 2019 Results Release Date and Conference Call Details

MISSISSAUGA, ON, July 31, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of...